RecruitingNCT07030062

Echocardiography Guided TAVR (Echo TAVR)

Transcatheter Aortic Valve Replacement With Echocardiography Guidance


Sponsor

Pan Xiangbin

Enrollment

20 participants

Start Date

Feb 18, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.


Eligibility

Inclusion Criteria3

  • symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2);
  • a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;
  • chronic kidney disease and refuse to receive contrast agents or radiation exposure.

Exclusion Criteria1

  • Required hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Fuwai Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07030062


Related Trials